Saturday 17 October 2026
Export BLLN’s income statement to Excel — free account
BillionToOne, Inc.
BLLN Healthcare Diagnostics & Research
BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024. In the quarter to June 2026, revenue grew 64.4%, EPS grew 817.3%, free cash flow grew 400.7% and total debt rose 74.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
98.06
4.67
−4.55%
Follow BLLN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 23.27% | 0.00% | 0.00% | 0.00% |
+5 more TTM periods Free account |
|
| 9.09% | 7.10% | 0.92% | (10.77%) | ||
ROIC |
34.10% | 38.70% | 24.01% | 0.00% | |
Return on Tangible Assets |
5.35% | 4.22% | 0.55% | (7.68%) | |
Average Days of Receivables |
68.79 | 63.11 | 49.79 | 51.10 | |
Free Cash Flow per Share |
0.71 | 0.57 | 0.99 | (0.39) | |
Free Cash Flow |
33.17 | 26.40 | 15.71 | (4.04) | |
Capital Expenditures |
(12.18) | (11.00) | (8.88) | (9.42) | |
| Other line items | |||||
Cash ROIC |
2.82% | 2.33% | 1.52% | (36.43%) | |
Accounts Receivable Turnover |
7.98 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
13.83 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
7.65 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
39.01 | 30.26 | 27.13 | 32.60 | |
Days of Inventory on Hand |
67.56 | 66.83 | 66.26 | 72.61 | |
Tax Rate |
(0.01) | (0.02) | (0.04) | 0.00 | |
Research and Development Expense of Revenue |
14.90% | 15.13% | 16.19% | 18.06% | |
Selling, General and Administrative Expense of Revenue |
45.47% | 45.06% | 46.88% | 49.43% | |
Share Based Compensation of Revenue |
6.43% | 5.66% | 5.22% | 6.32% | |
Interest Coverage |
1,056.15 | 556.49 | 168.66 | (13.51) | |
Operating CF/Net income |
1.37 | 1.50 | 8.43 | (0.31) | |
Depreciation/Fixed assets |
0.49 | 0.53 | 0.58 | 0.64 | |
Capex/Depreciation |
(0.99) | (0.93) | (0.75) | (0.79) | |
Revenue per Share |
8.56 | 7.72 | 19.22 | 23.73 | |
Operating CF per Share |
0.98 | 0.81 | 1.55 | 0.52 | |
Capex per Share |
(0.26) | (0.24) | (0.56) | (0.90) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.04 |
Columns are period end dates